InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Mineralys Therapeutics, Inc.

MLYS Clue Score35
United States Fiscal year ends December CIK 0001933414
$23.37 +4.42% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $23.37 +148.88% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 10 Feb 2023. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2022Operating income−31.5Net income−29.8EPS, diluted−5.77Fiscal year 2023Operating income−84.7Net income−71.9EPS, diluted−1.99Fiscal year 2024Operating income−192.4Net income−177.8EPS, diluted−3.66Fiscal year 2025Operating income−170.6Net income−154.7EPS, diluted−2.29
FY2022FY2023FY2024FY2025
Operating income −31.5 −84.7 −192.4 −170.6
Net income −29.8 −71.9 −177.8 −154.7
Growth
EPS, diluted −5.77 −1.99 −3.66 −2.29

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2022Operating cash flow−29.2Fiscal year 2023Operating cash flow−81.2Capital expenditure0.0Free cash flow−81.2Fiscal year 2024Operating cash flow−166.3Capital expenditure−0.1Free cash flow−166.4Fiscal year 2025Operating cash flow−142.4Capital expenditure−0.0Free cash flow−142.4
FY2022FY2023FY2024FY2025
Operating cash flow −29.2 −81.2 −166.3 −142.4
Capital expenditure n/a 0.0 −0.1 −0.0
Free cash flow n/a −81.2 −166.4 −142.4
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2022Cash87.7Shareholders’ equity−52.3Fiscal year 2023Cash49.3Shareholders’ equity241.2Fiscal year 2024Cash114.1Shareholders’ equity191.3Fiscal year 2025Cash172.9Shareholders’ equity646.7
FY2022FY2023FY2024FY2025
Cash 87.7 49.3 114.1 172.9
Shareholders’ equity −52.3 241.2 191.3 646.7

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Returns
n/a −29.8% −93.0% −23.9%
−26.0% −28.6% −86.4% −23.4%
Balance and payout
n/a n/a n/a 2.3%